Nitric oxide pathway in hypertrophied heart: New therapeutic uses of nitric oxide donors

Journal of Hypertension

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Ruiz Hurtado, Gema ^a,b   Delgado, Carmen ^a,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIV MONTPELLIER   (France)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

cardiac hypertrophy; cardiomyocyte; myocardium; nitric oxide; nitric oxide donors

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; ANGIOTENSIN 1 RECEPTOR; ARGININE; AVE 3085; AVE 9488; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HMR 1766; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LA 419; N(G),N(G) DIMETHYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE V; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

AORTA STENOSIS; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG TARGETING; HEART FAILURE; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PRESSURE GRADIENT; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH;

EID: 77957271700     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000388496.66330.b8     Document Type: Review

References (49)

1. Diwan A, Dorn GW II. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) 2007; 22:56-64.
2. Kannel WB, Cobb J. Left ventricular hypertrophy and mortality-results from the Framingham Study. Cardiology 1992; 81:291-298.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
4. Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 2010; 61:269-280.
5. Massion PB, Pelat M, Belge C, Balligand JL. Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol 2005; 142:144-150.
6. Matsuoka H, Nakata M, Kohno K, Koga Y, Nomura G, Toshima H, et al. Chronic l-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 1996; 27:14-18.
7. Lin Y, Wang LN, Xi YH, Li HZ, Xiao FG, Zhao YJ, et al. L-Arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways. Basic Clin Pharmacol Toxicol 2008; 103:124-130.
8. Ou ZJ, Wei W, Huang DD, Luo W, Luo D, Wang ZP, et al. l-Arginine restores endothelial nitric oxide synthase coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats. Am J Physiol Endocrinol Metab 2010; 298:E1131-E1139.
9. Simko F, Luptak I, Matuskova J, Krajcirovicova K, Sumbalova Z, Kucharska J, et al. L-Arginine fails to protect against myocardial remodelling in L-nameinduced hypertension. Eur J Clin Invest 2005; 35:362-368.
10. Brooks WW, Conrad CH, Robinson KG, Colucci WS, Bing OH. L-Arginine fails to prevent ventricular remodeling and heart failure in the spontaneously hypertensive rat. Am J Hypertens 2009; 22:228-234.
11. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, et al. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295:58-64.
12. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the L-arginine paradox and acts as a novel cardiovascular risk factor. J Nutr 2004; 134:2842S-2847S; discussion 2853S.
13. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005; 115:1221-1231.
14. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008; 117:2626-2636.
15. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 2010; 121:519-528.
16. Ruetten H, Dimmeler S, Gehring D, Ihling C, Zeiher AM. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 2005; 66:444-453.
17. Ichinose F, Bloch KD, Wu JC, Hataishi R, Aretz HT, Picard MH, et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 2004; 286:H1070-H1075.
18. Buys ES, Raher MJ, Blake SL, Neilan TG, Graveline AR, Passeri JJ, et al. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol 2007; 293:H620-H627.
19. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008; 118:818-827.
20. Westermann D, Riad A, Richter U, Jager S, Savvatis K, Schuchardt M, et al. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol 2009; 104:499-509.
21. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, Casadei B. Nnos gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation 2005; 112:3729-3737.
22. Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, Schuleri KH, et al. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation 2005; 112:3415-3422.
23. Loyer X, Gomez AM, Milliez P, Fernandez-Velasco M, Vangheluwe P, Vinet L, et al. Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. Circulation 2008; 117:3187-3198.
24. Barouch LA, Cappola TP, Harrison RW, Crone JK, Rodriguez ER, Burnett AL, et al. Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol 2003; 35:637-644.
25. Piech A, Dessy C, Havaux X, Feron O, Balligand JL. Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res 2003; 57:456-467.
26. Ruiz-Hurtado G, Fernandez-Velasco M, Mourelle M, Delgado C. La419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 2007; 50:1049-1056.
27. Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007; 100:1089-1098.
28. Sun Y, Carretero OA, Xu J, Rhaleb NE, Yang JJ, Pagano PJ, et al. Deletion of inducible nitric oxide synthase provides cardioprotection in mice with 2-kidney, 1-clip hypertension. Hypertension 2009; 53:49-56.
29. Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, et al. Exploiting cgmp-based therapies for the prevention of left ventricular hypertrophy: NO-and beyond. Pharmacol Ther 2009; 124:279-300.
30. Pilz RB, Casteel DE. Regulation of gene expression by cyclic GMP. Circ Res 2003; 93:1034-1046.
31. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5:755-768.
32. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109:366-398.
33. Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 2009; 191:309-339.
34. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP, et al. NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 2006; 148:853-859.
35. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58:488-520.
36. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5a prevents and reverses cardiac hypertrophy. Nat Med 2005; 11:214-222.
37. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with preexisting advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 2009; 53:207-215.
38. Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, et al. Expression, activity, and pro-hypertrophic effects of PDE5a in cardiac myocytes. Cell Signal 2008; 20:2231-2236.
39. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009; 119:408-416.
40. Konstantinos G, Petros P. Phosphodiesterase-5 inhibitors: future perspectives. Curr Pharm Des 2009; 15:3540-3551.
41. Linz W, Wohlfart P, Scholkens BA, Malinski T, Wiemer G. Interactions among ACE, kinins and NO. Cardiovasc Res 1999; 43:549-561.
42. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMGCOA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37:1450-1457.
43. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest 2007; 37:681-691.
44. Galderisi M, de Divitiis O. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 2008; 51:523-531.
45. Mahmarian JJ, Moye LA, Chinoy DA, Sequeira RF, Habib GB, Henry WJ, et al. Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial. Circulation 1998; 97:2017-2024.
46. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, Hess OM. Effect of NO donors on LV diastolic function in patients with severe pressureoverload hypertrophy. Circulation 1999; 99:2396-2401.
47. Megson IL, Leslie SJ. La-419, a nitric-oxide donor for the treatment of cardiovascular disorders. Curr Opin Invest Drugs 2009; 10:276-285.
48. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46:518-523.
49. Paulis L, Simko F. La419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling. Hypertension 2007; 50:1009-1011.